MedTrace Logo

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

NCT03553433 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-06-12

No results posted yet for this study

Summary

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

Conditions

  • Psoriasis of Scalp
  • Psoriasis Vulgaris

Interventions

DRUG

Apremilast 30mg

Anti-psoriatic drug

DRUG

Placebo Oral Tablet

Indistinguishable tablets not containing apremilast, Placebo Oral Tablet

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Alexander Navarini, MD PhD · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2019-12-31
Completion
2020-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553433 on ClinicalTrials.gov